




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, G01N 33/566, A61K 38/17, C07K 16/28, A61K 39/395, C12N 15/62		A1	(11) International Publication Number: WO 00/50589
			(43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/US00/04326		(81) Designated States: AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 February 2000 (18.02.00)			
(30) Priority Data: 60/121,170 22 February 1999 (22.02.99) US 60/158,566 8 October 1999 (08.10.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): <u>CHIARI, Rita</u> , [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE); <u>COULIE, Pierre</u> [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE); <u>BOON-FALLEUR, Thierry</u> [BE/BE]; 7459, avenue Hippocrate, B-1200 Brussels (BE).			
(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).			
(54) Title: TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES			



(57) Abstract

The invention describes HLA class II binding peptides encoded by the EphA3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4⁺T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the EphA3 gene.